artefenomel
Small moleculeexperimental
Clinical trial activity
21 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00928083)
Timeline
Indications
Mechanism of action
- PlasmodiumINHIBITOR
Plasmodium inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
c1cc([C@H]2CC[C@]3(CC2)OO[C@]2(O3)C3CC4CC(C3)CC2C4)ccc1OCCN1CCOCC1- Mol. weight
- 469.62 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1828820 ↗
Also known as
- artefenomel
- artefenomel
- artefenomel
- oz439
- oz439
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03660839 | Phase 2 | Sep 5, 2018 | Sanofi |
| NCT04264130 | Phase 2 | Jul 31, 2018 | Centre de Recherche Médicale de Lambaréné |
| NCT04069221 | Phase 1 | Feb 28, 2017 | Medicines for Malaria Venture |
| NCT02573857 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2015 | Clinical Neuroscience Solutions, Inc., Medicines for Malaria Venture, Q-Pharm, University of Queensland |
| NCT02497612 | Phase 2 | Jul 25, 2015 | Sanofi |
| NCT02387580 | Phase 1 | Apr 1, 2015 | Medicines for Malaria Venture, Quotient |
| NCT02431650 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Clinical Neuroscience Solutions, Inc., Government of Australia, Medicines for Malaria Venture, Q-Pharm, University of Queensland |
| NCT02389348 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2015 | Clinical Neuroscience Solutions, Inc., Medicines for Malaria Venture, Q-Pharm, University of Queensland |
| NCT02083380 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2014 | Medicines for Malaria Venture |
| NCT02083406 | Phase 1 | Jul 1, 2014 | Medicines for Malaria Venture, Quotient |
| NCT01958619 | Phase 1 | Oct 1, 2013 | Medicines for Malaria Venture, Richmond Pharmacology |
| NCT01853475 | Phase 1 | Apr 1, 2013 | Medicines for Malaria Venture, Richmond Pharmacology |
| NCT01713621 | Phase 2 | Mar 1, 2013 | Mahidol University, Medicines for Malaria Venture |
| NCT01713608 | Phase 1 | Nov 1, 2012 | Medicines for Malaria Venture |
| NCT01732588 | Phase 1 | Nov 1, 2012 | Medicines for Malaria Venture |
| NCT02453581 | Phase 1 | Sep 1, 2012 | Medicines for Malaria Venture, Q-Pharm, University of Queensland |
| NCT01660022 | Phase 1 | Sep 1, 2012 | Cross Research S.A., Medicines for Malaria Venture |
| NCT01615822 | Phase 1 | Aug 1, 2012 | Medicines for Malaria Venture, University of Cape Town |
| NCT01383096 | Phase 1 | Apr 1, 2012 | INC Research, Medicines for Malaria Venture, Monash University, Nucleus Network Ltd |
| NCT01213966 | Phase 2 | Oct 1, 2010 | Mahidol University, Medicines for Malaria Venture |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medicines for Malaria Venture | Academic/Hospital | 18 | 18 | 3 | 2009 |
| Q-Pharm | For profit | 4 | 0 | 2 | 2012 |
| University of Queensland | Academic/Hospital | 4 | 0 | 2 | 2012 |
| Clinical Neuroscience Solutions, Inc. | For profit | 3 | 0 | 1 | 2015 |
| Mahidol University | Academic/Hospital | 2 | 0 | 1 | 2010 |
| Quotient | For profit | 2 | 0 | 1 | 2014 |
| Richmond Pharmacology | For profit | 2 | 0 | 1 | 2013 |
| Sanofi | For profit | 2 | 2 | 1 | 2015 |
| Centre de Recherche Médicale de Lambaréné | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Comprehensive Clinical Development, Inc. | For profit | 1 | 0 | 1 | 2009 |
| Cross Research S.A. | For profit | 1 | 0 | 1 | 2012 |
| Government of Australia | Government | 1 | 0 | 1 | 2015 |
| INC Research | For profit | 1 | 0 | 1 | 2012 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2012 |
| University of Cape Town | Academic/Hospital | 1 | 0 | 1 | 2012 |
16 organizations
Page 1 / 1